STAAR SURGICAL COMPANY

NASDAQ: STAA (STAAR Surgical Company)

最近更新时间: 09 Nov, 4:38AM

26.55

-0.08 (-0.30%)

前收盘价格 26.63
收盘价格 26.41
成交量 1,941,757
平均成交量 (3个月) 1,008,445
市值 1,310,665,984
预期市盈率 (P/E Forward) 69.44
价格/销量 (P/S) 5.65
股市价格/股市净资产 (P/B) 3.68
52周波幅
13.50 (-49%) — 30.88 (16%)
利润日期 5 Nov 2025
营业毛利率 -25.46%
营业利益率 (TTM) -81.43%
稀释每股收益 (EPS TTM) -1.44
季度收入增长率 (YOY) -44.90%
季度盈利增长率 (YOY) 107.20%
总债务/股东权益 (D/E MRQ) 10.48%
流动比率 (MRQ) 4.78
营业现金流 (OCF TTM) -11.69 M
杠杆自由现金流 (LFCF TTM) 10.73 M
资产报酬率 (ROA TTM) -5.90%
股东权益报酬率 (ROE TTM) -19.14%

市场趋势

短期 中期
行业 Medical Instruments & Supplies (US) 看涨 混合的
Medical Instruments & Supplies (全球的) 混合的 看跌
股票 STAAR Surgical Company 看涨 看跌

AIStockmoo 评分

0.7
分析师共识 2.0
内部交易活动 4.0
价格波动 -4.5
技术平均移动指标 2.5
技术振荡指标 -0.5
平均 0.70

相关股票

股票 市值 DY P/E(TTM) P/B
STAA 1 B - - 3.68
MMSI 5 B - 44.30 3.39
LMAT 2 B 0.91% 38.12 4.96
ATRC 2 B - - 3.77
AZTA 2 B - 70.58 0.930
PLSE 887 M - - 10.01

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

部门 Healthcare
行业 Medical Instruments & Supplies
投资方式 Small Growth
内部持股比例 0.64%
机构持股比例 109.43%

所有权

姓名 日期 持有股份
Defender Capital, Llc. 30 Sep 2025 701,277

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
02 Dec 2025 公告 Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
10 Nov 2025 公告 Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
07 Nov 2025 公告 STAAR Surgical Announces Amendments to Alcon Merger Agreement
06 Nov 2025 公告 Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
05 Nov 2025 公告 STAAR Surgical Reports Third Quarter 2025 Results
04 Nov 2025 公告 Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
04 Nov 2025 公告 Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
31 Oct 2025 公告 Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
27 Oct 2025 公告 STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
24 Oct 2025 公告 Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
24 Oct 2025 公告 Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
23 Oct 2025 公告 Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
22 Oct 2025 公告 Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors
20 Oct 2025 公告 Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
20 Oct 2025 公告 STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
20 Oct 2025 公告 Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
17 Oct 2025 公告 Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
16 Oct 2025 公告 STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon
15 Oct 2025 公告 Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
14 Oct 2025 公告 Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
10 Oct 2025 公告 Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
08 Oct 2025 公告 Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
08 Oct 2025 公告 STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
08 Oct 2025 公告 Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
07 Oct 2025 公告 Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
06 Oct 2025 公告 Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
06 Oct 2025 公告 STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims
06 Oct 2025 公告 STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
06 Oct 2025 公告 Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
03 Oct 2025 公告 Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
30 Sep 2025 公告 Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
26 Sep 2025 公告 STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
24 Sep 2025 公告 Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
22 Sep 2025 公告 STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
22 Sep 2025 公告 Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
16 Sep 2025 公告 STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票